🧬 23andMe In Bankruptcy

+ Powell Signals Rate Cuts Ahead, But “No Hurry”

Good afternoon! Boeing wants a do-over on its guilty plea for defrauding the FAA before two fatal 737 MAX crashes. The company is negotiating with the Justice Department to either withdraw or lighten the terms of a Biden-era deal that required a $243 million fine, $455 million in safety upgrades, and hiring an independent monitor. If successful, it would mark one of the Trump administration’s most significant shifts toward easing white-collar penalties.

The original deal followed a probation period that was about to expire when a door panel blew off an Alaska Airlines 737 MAX in January, triggering fresh scrutiny. Families of the 346 victims from the 2018 and 2019 crashes have pushed for harsher penalties, arguing Boeing should admit to causing the deaths. A judge has given both sides until April 11 to propose changes — but backing out entirely could face serious pushback.

MARKETS

*Stock data as of market close*

  • Stocks jumped Monday as reports surfaced that Trump’s next round of tariffs might be more targeted than expected. The S&P 500 rose 1.8%, the Dow gained 1.4%, and the Nasdaq climbed 2.3% as investors welcomed signs of a softer trade stance.

  • Tech stocks led the rally, with Tesla up 12% and Amazon and Nvidia adding over 3%. Microsoft and Apple also posted gains, helping the Nasdaq notch its best day in weeks.

STOCKS
Winners & Losers

What’s up 📈

  • Tesla soared 11.93%, making it the top performer in the S&P 500 after the FBI unveiled a Tesla threats task force. ($TSLA)

  • ViaSat jumped 14.42% after Deutsche Bank upgraded the stock to buy, citing multiple monetization opportunities. ($VSAT)

  • AZEK surged 17.32% after James Hardie agreed to acquire the outdoor products manufacturer for $9 billion in cash and stock. ($AZEK)

  • FedEx gained 5.21% after Jefferies upgraded the stock to buy, citing strong cost-cutting measures that could boost profitability. ($FDX)

  • Pinterest climbed 5% following an upgrade from Guggenheim to buy, which said the stock’s recent pullback offers an attractive entry point. ($PINS)

  • Steel Dynamics rose 3.25% after UBS upgraded the stock to buy, citing tariff protection as a catalyst for higher prices. ($STLD)

  • Nucor added 4.42% following a UBS upgrade to buy, highlighting benefits from U.S. steel tariffs. ($NUE)

  • Generac advanced 4.68% after Bank of America reinstated coverage with a buy rating, citing increased demand for backup power. ($GNRC)

What’s down 📉

  • 23andMe plummeted 59.22% after the DNA testing company filed for Chapter 11 bankruptcy and CEO Anne Wojcicki resigned. ($ME)

  • James Hardie sank 17.18% after announcing the acquisition of AZEK in a cash and stock deal worth around $9 billion. ($JHX)

  • Bayer dropped 7.07% after a Georgia jury ruled against its subsidiary Monsanto in a Roundup weedkiller lawsuit, awarding $2.1 billion to plaintiffs. ($BAYRY)

BANKRUPTCY
23andMe’s DNA Test Comes Back Negative — For Profitability

23andMe’s DNA test just confirmed its worst fear: bankruptcy. The once high-flying genetic testing company has filed for Chapter 11 after failing to secure a buyer, with only 550,000 paying subscribers left on board — a far cry from the 10 million customer goal it pitched to investors back in 2021. Despite gathering genetic data from over 15 million people, the company never found a way to turn one-time test kit buyers into long-term customers. Now, 23andMe is hoping to sell off its assets — including that treasure trove of DNA data — through a court-supervised auction.

The SPAC Hangover: 23andMe’s rise and fall is a classic SPAC cautionary tale. The company went public at a $3.5 billion valuation in 2021 via a special-purpose acquisition company (SPAC) — essentially a shortcut to going public without the usual IPO hurdles. But like other SPAC darlings (WeWork, Virgin Orbit, and Nikola, to name a few), 23andMe quickly realized that a public listing doesn’t magically create a sustainable business model. Its attempt to pivot from genetic testing to drug development failed to generate meaningful revenue, and the subscription-based model never gained traction.

Hacking, Lawsuits, and a Leadership Shake-Up
The road to bankruptcy wasn’t just paved with bad business decisions. A 2023 data breach exposed information from around seven million customers, leading to more than 35,000 legal claims. Meanwhile, Anne Wojcicki, the company’s co-founder and longtime CEO, tried to take the company private earlier this year — but the board rejected the offer. Wojcicki has since stepped down as CEO, though she’ll stay on the board.

Will Your DNA End Up On the Auction Block?
Here’s the part that makes customers sweat: that DNA database is one of 23andMe’s most valuable assets — and it could be sold to the highest bidder. The company insists that any buyer will have to follow existing privacy laws, but that’s cold comfort when you’re wondering whether your genetic blueprint will soon belong to a Big Pharma giant or a data mining firm. If you’d rather not take that risk, now might be the time to hit “delete.”

From Genetic Goldmine to SPAC Cautionary Tale: 23andMe’s fall isn’t just about flawed business strategy — it’s about the broader SPAC boom that turned into a bust. Nearly half of the 450 companies that went public via SPACs after the pandemic have seen their valuations crater by over 90%. 23andMe’s genetic data may still be valuable — but as far as investors are concerned, the company’s future looks like a recessive trait.

NEWS
Market Movements

EUROPE
Novo Nordisk Gets EU-Surped as SAP Takes Top Spot in Europe

Novo Nordisk has been dethroned as Europe’s most valuable company — and weight-loss drug disappointment is to blame. The Danish pharma giant’s stock has been in a steady decline since last summer, capped off by the underwhelming trial results for CagriSema, its next-generation obesity drug. In a recent study, patients without Type 2 diabetes on CagriSema lost 22.7% of their weight, down from the 25% expected — while those with Type 2 diabetes shed just 15.7%. That’s not exactly the blockbuster performance investors were hoping for.

Novo’s stock has fallen 18% this year alone, erasing billions in market value and leaving the door wide open for a new king of European markets. Enter SAP.

SAP Rides the AI Wave
German software giant SAP has taken the crown with a market cap of around $339 billion, thanks to a 40% surge in its stock price over the past year. CEO Christian Klein’s strategy of shifting from traditional software licenses to subscription-based cloud services has paid off, especially with AI-driven products driving higher margins. SAP’s cloud-based model provides the kind of predictable, recurring revenue that Wall Street loves — and it's working.

SAP’s success has also fueled Germany’s DAX index, which is up almost 19% year-to-date. In fact, SAP alone is responsible for nearly 40% of the index’s gains this year. The company is projecting a 12% revenue increase in 2025, which would be its fastest growth rate in over a decade.

Novo’s New Strategy
Novo isn’t sitting still. The company announced it's spending up to $2 billion to license a Chinese-made weight-loss drug that could rival Ozempic — a clear sign it’s looking to reinforce its position in the weight-loss market. But investors aren’t convinced just yet, and the company’s market cap now sits just under SAP’s.

Tech vs. Pharma: SAP’s rise underscores the broader shift in market sentiment toward tech over pharma. While Novo’s weight-loss dominance made it the darling of European markets in 2021 and 2022, AI is now the hot commodity. Novo could still make a comeback if it delivers better results with its next round of drug trials — but for now, SAP is sitting comfortably on top.

Calendar
On The Horizon

Tomorrow

Tomorrow brings a pulse check on housing and consumer sentiment. The Case-Shiller home price index will offer insights into the state of the real estate market, while the Conference Board’s consumer confidence report will reveal how optimistic (or not) Americans are feeling about the economy.

After Market Close:

  • GameStop’s latest rally seems more about Bitcoin buzz than business fundamentals. Rumors are swirling that the company plans to buy bitcoin, which shareholders will want clarity on tomorrow.

    Beyond crypto, GameStop faces a bigger threat from tariffs. The gaming industry leans on cheap overseas electronics, and with game studios increasingly favoring digital sales over physical copies, GameStop’s retail-heavy model could take a serious hit. ($GME)

NEWS
The Daily Rundown

RESOURCES
The Federal Reserve Resource

Join our small yet growing subreddit 🚀: https://www.reddit.com/r/investinq/

Wall Street Reads 💎 (Best Books):

Check out our latest issues 🎯: https://investinq.beehiiv.com